Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0792 • ACR Convergence 2021
Remission Rates of Patients with Rheumatoid Arthritis in a Tertiary Care
Nils Gildemeister¹, Imke Redeker², Bjoern Buehring¹, Ioana Andreica¹, David Kiefer³, Xenofon Baraliakos¹, Juergen Braun¹ and Uta Kiltz¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²German Rheumatism Research Centre (DRFZ), Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany
Background/Purpose: The main goal of treatment for patients (pts.) with rheumatoid arthritis (RA) is to achieve remission, in order to both, preserve physical function and…
Abstract Number: 0808 • ACR Convergence 2021
Lower Serum MIP-1β Level Is Associated with CsDMARDs Response in Patients with Early Rheumatoid Arthritis
Isaac Cheng¹, Ho So², Martin Li¹, Evelyn Chow¹, Chun Kwok Wong¹ and Lai-Shan Tam³, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²CUHK, Hong Kong, China, ³Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: The use of treat-to-target (T2T) strategy in managing early rheumatoid arthritis (ERA) had been highly advocated in the past decades. Various international guideline utilized…
Abstract Number: 0827 • ACR Convergence 2021
Discontinuation Rate of Tofacitinib as Monotherapy Is Similar Compared to Combination Therapy with Methotrexate in Rheumatoid Arthritis Patients: Pooled Data from Two Rheumatoid Arthritis Registries in Canada
Mohammad Movahedi¹, Denis Choquette², Louis Coupal², Angela Cesta³, Xiuying Li³, Edward Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁴Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). We previously…
Abstract Number: 0843 • ACR Convergence 2021
Prevalence and Trends of Infections in Hospitalized Patients with Rheumatoid Arthritis in the United States
Pushti Khandwala¹, Anila Hussain² and Devashish Desai¹, ¹Crozer Chester Medical Center, Glen Mills, PA, ²Crozer Chester Medical Center, Glen Mills
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing infections as compared to the patients without the diagnosis, and this risk is further…
Abstract Number: 1003 • ACR Convergence 2021
Significant Enrichment of Pathogenic CD206+CD163+ Macrophages in Rheumatoid Arthritis Synovial Tissue with Distinct Transcriptional Signatures
Megan Hanlon¹, Mary Canavan², Nuno Neto³, Qingxuan Song⁴, Phil Gallagher⁵, Ronan Mullan⁶, Conor Hurson⁷, Barry Moran³, Michael Monaghan³, Sunil Nagpal⁸, Douglas Veale⁹ and Ursula Fearon³, ¹Molecular Rheumatology, Dublin, Ireland, ²Trinity College, Santry, Ireland, ³Trinity College Dublin, Dublin, Ireland, ⁴Janssen Research & Development LLC, Spring House, PA, ⁵St Vincent's Hospital, Dublin, Ireland, ⁶Tallaght University Hospital, Dublin, Ireland, ⁷St Vincents University Hospital, Dublin, Ireland, ⁸Janssen Research, Collegeville, PA, ⁹University College Dublin, Dublin, Ireland
Background/Purpose: Synovial tissue macrophages are an exquisitely plastic pool of innate cells that play a key role in RA disease progression. However, the precise nature,…
Abstract Number: 1091 • ACR Convergence 2021
Serum Metabolomic Profiling Identifies Potential Biomarkers in Arthritis in the Elderly
Martha Cedeno¹, Jessica Murillo Saich¹, Roxana Coras², Anahy Maria Brandy-Garcia³, Agueda Prior-Español⁴, Lourdes Mateo⁵, Melania Martinez-Morillo⁵ and Monica Guma⁶, ¹University of California San Diego, La Jolla, CA, ²University of California San Diego/Department of Medicine, Autonomous University of Barcelona, San Diego, CA, ³Hospital Germans Trias i Pujol, Badalona, Spain, ⁴Department of Rheumatology, Germans Trias i Pujol. University Hospital, Badalona, Spain, ⁵Department of Rheumatology, Germans Trias i Pujol. University Hospital, Barcelona, Spain, ⁶University of California San Diego/San Diego VA Healthcare Service/Department of Medicine, Autonomous University of Barcelona, La Jolla, CA
Background/Purpose: Elderly-onset RA (EORA) and polymyalgia rheumatica (PMR) are common rheumatic diseases in the elderly, but their pathogenesis is not yet fully understood. Seronegative EORAneg…
Abstract Number: 1203 • ACR Convergence 2021
A Change in a Patient Informed Clinical Disease Activity Index (PTCDAI) Is Similar to Their Rheumatologists CDAI When Following Patients with Early RA in the Canadian Early Arthritis Cohort (CATCH) Study
Vivian Bykerk¹, Orit Schieir², Marie-France Valois³, Glen Hazlewood⁴, Carol Hitchon⁵, Gilles Boire⁶, Diane Tin⁷, Louis Bessette⁸, Edward Keystone⁹, Carter Thorne⁷, Janet Pope¹⁰ and Susan Bartlett³, ¹Division of Rheumatology, Hospital for Special Surgery, New York City, NY, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Laval University, Québec City, QC, Canada, ⁹Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ¹⁰University of Western Ontario, London, ON, Canada
Background/Purpose: The Clinical Disease Activity Index (CDAI) is a frequently used composite measure by rheumatologists (MD) in routine care used to guide target-based treatment decisions.…
Abstract Number: 1219 • ACR Convergence 2021
Machine Learning Based Prediction Model for Responses of bDMARDs in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis
Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Jaejoon Lee, Eun-Mi Koh and Hoon-Suk Cha, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Background/Purpose: Few studies on rheumatoid arthritis (RA) have generated machine learning models to predict biologic disease-modifying antirheumatic drugs (bDMARDs) responses; however, these studies included insufficient…
Abstract Number: 1235 • ACR Convergence 2021
Treatment Effect of Baricitinib on Fatigue: Mediation Analysis Results from Two Phase 3 Trials
Bruno Fautrel¹, Bochao Jia², Jianmin Wu³, Ju Ji², Julie Birt², Ewa Haladyj² and Tsutomu Takeuchi⁴, ¹Pitié Salpêtrière Hospital, APHP, Sorbonne Université, Paris, France, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianaplolis, IN, ⁴Div. Rheumatology, Keio University, Tokyo, Japan
Background/Purpose: Fatigue is very common in rheumatoid arthritis (RA) and impairs patient quality of life. Baricitinib (BARI) improved fatigue, pain and other patient-reported outcomes (PROs)…
Abstract Number: 1251 • ACR Convergence 2021
Serum B Cell Activating Factor Reflects Good EULAR Response to TNF Inhibition in Patients with Rheumatoid Arthritis
Borja Hernandez-Breijo¹, Ioannis Parodis², Chamaida Plasencia-Rodríguez³, Mariana Díaz-Almirón⁴, Ana Martínez-Feito⁵, Marta Novella-Navarro³, Dora Pascual-Salcedo¹ and Alejandro Balsa³, ¹Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain, ²Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden and Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden, ³Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Rheumatology, La Paz University Hospital, Madrid, Spain, ⁴Biostatistics Unit, Hospital La Paz Institute for Health Research-IdiPAZ, Madrid, Spain, ⁵Immuno-Rheumatology Research Group, Hospital La Paz Institute for Health Research-IdiPAZ, Immunology Unit, La Paz University Hospital, Madrid, Spain
Background/Purpose: The latest breakthroughs in the pathophysiology of rheumatoid arthritis (RA) highlighted the activation of B cells as a trigger of the joint flare initiation…
Abstract Number: 1453 • ACR Convergence 2021
Lung Interleukin-33 Is Elevated in Rheumatoid Arthritis-Associated Lung Disease
Rohit Gaurav¹, Ted Mikuls¹, Geoffrey Thiele¹, Bryant England¹, Madison Wolfe¹, Kristina Bailey¹, Amy Nelson¹, Michael Duryee¹, Debra Romberger¹, Dana Ascherman² and Jill Poole¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The alarmin interleukin (IL)-33 is a member of the IL-1 cytokine family that is rapidly released from the nucleus of a variety of lung…
Abstract Number: 1650 • ACR Convergence 2021
Identifying Trajectories and Endotypes in the Evolution of Pre-Rheumatoid Arthritis with Autoantibody Testing and Artificial Adaptive System Analysis
Paolo Massimo Buscema¹, Giulia Massini², Francesca Della Torre², Masoud Asadi-Zeydabadi³, Colin O'Donnell⁴, Francis Newman⁵, Randall Tagg³, Weldon Lodwick⁵, Christopher Collora⁴, Marie Feser⁴, LauraKay Moss⁴, William Robinson⁶, Geoffrey Thiele⁷, Ted Mikuls⁷, Jess Edison⁸, V. Michael Holers⁴ and Kevin Deane⁹, ¹Semeion Research Center of Sciences of Communication; University of Colorado Denver Department of Mathematical and Statistical Sciences, Rome, Italy, ²Semeion Research Center of Sciences of Communication, Rome, Italy, ³University of Colorado Denver Department of Physics, Denver, CO, ⁴University of Colorado Denver, Aurora, CO, ⁵University of Colorado Denver Department of Mathematical and Statistical Sciences, Denver, CO, ⁶Stanford University, Palo Alto, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹University of Colorado Denver, Denver, CO
Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period that can be defined by elevations of antibodies to citrullinated protein antibodies (ACPA), rheumatoid factor (RF), and…
Abstract Number: 1666 • ACR Convergence 2021
Association of Objectively Measured Sleep Characteristics with Rheumatoid Arthritis Disease Activity
Patricia Katz¹, Sarah Patterson², Mary Nakamura³, Aric Prather¹, Laura Trupin⁴, Stephanie Rush¹ and Katie Stone¹, ¹University of California San Francisco, San Francisco, CA, ²University of California San Francisco, Pacifica, CA, ³UCSF/SFVAHCS, San Francisco, CA, ⁴UC San Francisco, San Francisco, CA
Background/Purpose: A large proportion of individuals with rheumatoid arthritis (RA), between 45%-70%, report sleep problems. Despite frequent reports of sleep problems, however, studies using objective…
Abstract Number: 1682 • ACR Convergence 2021
Impact of Type, Dose and Duration of Oral Polyunsaturated Fatty Acid Supplementation on Disease Activity in Inflammatory Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Johanna Sigaux¹, Sylvain Mathieu², Yann N guyen³, Pauline Sanchez⁴, Jean-Guillaume LETAROUILLY⁵, Martin Soubrier², sebastien czernichow⁶, Rene-Marc FLIPO⁷, Jeremie Sellam⁸ and Claire Daïen⁴, ¹Department of Rheumatology, Hôpital Avicenne, APHP, INSERM U1125, Université Sorbonne Paris Nord, Bobigny, France, ²Department of Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, ³Department of Internal Medicine, Hôpital Beaujon, APHP nord, Université de Paris, F-92100 Clichy, France, Paris, France, ⁴Department of Rheumatology, CHU de Montpellier, & University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier FRANCE University of Montpellier, PhyMedExp, INSERM, CNRS UMR, Montpellier, France, ⁵Rheumatology Department, University Hospital of Lille, Lille, France, ⁶Department of Nutrition, Specialized Obesity Center, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France, ⁷Rheumatology Department, Lille University Hospital, Lille, France, ⁸INSERM UMRS_938, Sorbonne Université, St-Antoine Hospital, Paris, France, Paris, France
Background/Purpose: This systematic literature review and meta-analysis aimed to better estimate the effect of oral supplementation with polyunsaturated fatty acid (PUFA; omega (n)-3 and n-6)…
Abstract Number: 1698 • ACR Convergence 2021
Integrated Safety Analysis Update for Filgotinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Receiving Treatment over a Median of 2.2 Years
Kevin Winthrop¹, Yoshiya Tanaka², Tsutomu Takeuchi³, Alan Kivitz⁴, Mark Genovese⁵, Alena Pechonkina⁶, Franziska Matzkies⁶, Beatrix Bartok⁷, Kun Chen⁶, Deyuan Jiang⁶, Iyabode Tiamiyu⁶, Robin Besuyen⁸, Sander Strengholt⁹, Gerd Burmester¹⁰ and Jacques-Eric Gottenberg¹¹, ¹Oregon Health & Science University, Portland, OR, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Div. Rheumatology, Keio University, Tokyo, Japan, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Gilead Sciences, Inc., Sunnyvale, CA, ⁶Gilead Sciences, Inc., Foster City, CA, ⁷Gilead Sciences, Inc., La Jolla, CA, ⁸Galapagos BV, Leiden, Netherlands, ⁹Galapagos, BV, New York, NY, ¹⁰Charité University Medicine Berlin, Berlin, Germany, ¹¹National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France
Background/Purpose: The preferential Janus kinase (JAK)-1 inhibitor filgotinib (FIL) significantly improved signs and symptoms of RA in Phase 2 and 3 trials,1–5 and FIL is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].